Your cart is empty
Start Shopping$55.00
This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.
Molecular Formula | C₃₈H₄₉N₉O₅ |
CAS Number | 170851-70-4 |
Molar Mass | 711.85 g/mol |
Amino Acid Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
PubChem CID | 9831659 |
Primary Research Area |
Selective Growth Hormone Secretagogue Ghrelin/GHS Receptor Agonist Longitudinal Bone Growth Gastrointestinal Motility Disorders (Postoperative Ileus) Muscle Growth Metabolism Bone Density |
Purity | >99% |
Research Summary | Description |
---|---|
The benefits of Ipamorelin growth hormone |
Summary: This article states that Ipamorelin increases growth hormone levels by stimulating the hypothalamus, leading to increased muscle mass and strength, as well as fat loss due to increased metabolism and lipolysis. It also notes benefits such as improved workouts and recovery, reduced body fat, increased energy, and deeper sleep. Citation: NYMD Center. (n.d.). The Benefits of Ipamorelin Growth Hormone. |
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats |
Summary: This study demonstrated that Ipamorelin dose-dependently increased the longitudinal bone growth rate (LGR) and body weight gain in adult female rats. Citation: Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113. |
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus |
Summary: This study showed that Ipamorelin accelerated gastric emptying and intestinal transit in a rodent model of postoperative ileus (POI). This effect is mediated by its action on ghrelin receptors located on cholinergic neurons in the gut. Citation: Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534. |
Ipamorelin, the first selective growth hormone secretagogue |
Summary: This study identified Ipamorelin as the first selective growth hormone secretagogue. This selectivity means it stimulates GH release without significantly affecting other hormones like adrenocorticotropic hormone (ACTH) and cortisol, unlike some other GH-releasing peptides. Citation: Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. |
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients |
Summary: This human clinical trial investigated the efficacy of Ipamorelin in managing postoperative ileus (POI), a common complication after bowel surgery, by leveraging its ghrelin mimetic properties to improve gastrointestinal motility. Patients undergoing bowel resection received either Ipamorelin or placebo. While the study did not reach statistical significance for its primary endpoints (time to first tolerated meal and first bowel movement) when comparing the entire Ipamorelin group to placebo, some data suggested a trend towards shorter times to return of gastrointestinal function, particularly in patients undergoing open laparotomy. Citation: Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. |
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers |
Summary: This study focused on the pharmacokinetic and pharmacodynamic properties of Ipamorelin in healthy human volunteers. It characterized how Ipamorelin is absorbed, distributed, metabolized, and excreted in the body, and how these processes relate to its effect on GH release. The study found that Ipamorelin significantly increases plasma GH levels in humans, with peak concentrations typically occurring within an hour of administration, and that it has a relatively short half-life (approximately 2 hours). Citation: Gobburu, J., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1324–1330. |
Summary: This article states that Ipamorelin increases growth hormone levels by stimulating the hypothalamus, leading to increased muscle mass and strength, as well as fat loss due to increased metabolism and lipolysis. It also notes benefits such as improved workouts and recovery, reduced body fat, increased energy, and deeper sleep.
Citation: NYMD Center. (n.d.). The Benefits of Ipamorelin Growth Hormone.
Summary: This study demonstrated that Ipamorelin dose-dependently increased the longitudinal bone growth rate (LGR) and body weight gain in adult female rats.
Citation: Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
Summary: This study showed that Ipamorelin accelerated gastric emptying and intestinal transit in a rodent model of postoperative ileus (POI). This effect is mediated by its action on ghrelin receptors located on cholinergic neurons in the gut.
Citation: Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534.
Summary: This study identified Ipamorelin as the first selective growth hormone secretagogue. This selectivity means it stimulates GH release without significantly affecting other hormones like adrenocorticotropic hormone (ACTH) and cortisol, unlike some other GH-releasing peptides.
Citation: Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
Summary: This human clinical trial investigated the efficacy of Ipamorelin in managing postoperative ileus (POI), a common complication after bowel surgery, by leveraging its ghrelin mimetic properties to improve gastrointestinal motility. Patients undergoing bowel resection received either Ipamorelin or placebo. While the study did not reach statistical significance for its primary endpoints (time to first tolerated meal and first bowel movement) when comparing the entire Ipamorelin group to placebo, some data suggested a trend towards shorter times to return of gastrointestinal function, particularly in patients undergoing open laparotomy.
Citation:
Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534.
Summary: This study focused on the pharmacokinetic and pharmacodynamic properties of Ipamorelin in healthy human volunteers. It characterized how Ipamorelin is absorbed, distributed, metabolized, and excreted in the body, and how these processes relate to its effect on GH release. The study found that Ipamorelin significantly increases plasma GH levels in humans, with peak concentrations typically occurring within an hour of administration, and that it has a relatively short half-life (approximately 2 hours).
Citation:
Gobburu, J., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1324–1330.
Your cart is empty
Start Shopping